LD-2 disclosure · 2nd Quarter - Report
ASSOCIATION FOR ACCESSIBLE MEDICINES
Client
- Location
- District of Columbia · United States of America
Registrant
- Description
- Association representing the interests of the generic pharmaceutical industry.
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
5 issuesPharmacy
Prescription Drug Costs. Public Law No. 119-60: National Defense Authorization Act for Fiscal Year 2026. Drug Shortages. H.R.5526/S.1954: Biosimilar Red Tape Elimination Act (BRTEA). To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes (H.R.1051). S.1414/H.R.__: Expedited Access to Biosimilars Act. S.3469: BIOSECURE Act of 2025. Quotas on Controlled Substances. Hassan Purple Book Proposal. H.R.8269/S.3788: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act. American Made Medicines Act. PBM Bid Transparency. H.R.7148: Consolidated Appropriations Act, 2026 as it relates to PBM reforms and Q1/Q2. H.R.8339: Drug Origin Transparency Act of 2026.
LobbyistsKARIN HESSLER · PETER KELBEL · ILHAAM JAFFER · JOHN MURPHY · MARK RATNER · ALEX KEETON
TargetedSENATE · HOUSE OF REPRESENTATIVES · Congressional Budget Office (CBO) · White House Office · Health & Human Services, Dept of (HHS) · Food & Drug Administration (FDA) · Centers For Medicare and Medicaid Services (CMS) · Drug Enforcement Administration (DEA)
Medicare/Medicaid
Medicare Part D Reform. Medicaid Rebate Penalty. Medicare/Medicaid Inflation Penalties. Medicare Conditions of Participation. CMS RFC on Domestic Manufacturing. CMS Final Rule on Bona Fide Service Fees. HCPCS Codes. Tiering. PBM Bid Transparency.
LobbyistsKARIN HESSLER · PETER KELBEL · ILHAAM JAFFER · JOHN MURPHY · MARK RATNER · ALEX KEETON
